Cargando…

Treatment of Chronic HCV Infection in Special Populations

The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoefs, John, Aulakh, Vikramjit S.
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1415846/
https://www.ncbi.nlm.nih.gov/pubmed/16614746
_version_ 1782127131057192960
author Hoefs, John
Aulakh, Vikramjit S.
author_facet Hoefs, John
Aulakh, Vikramjit S.
author_sort Hoefs, John
collection PubMed
description The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined that respond less well to routine treatment including African Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-responders in general. Early viral kinetics can be used to define response or non-response and these results can be used to modify subsequent treatment length and dose.
format Text
id pubmed-1415846
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-14158462006-04-13 Treatment of Chronic HCV Infection in Special Populations Hoefs, John Aulakh, Vikramjit S. Int J Med Sci Review The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined that respond less well to routine treatment including African Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-responders in general. Early viral kinetics can be used to define response or non-response and these results can be used to modify subsequent treatment length and dose. Ivyspring International Publisher 2006-04-01 /pmc/articles/PMC1415846/ /pubmed/16614746 Text en © Ivyspring International Publisher. This is an open access article. Reproduction is permitted for personal and noncommerical use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Review
Hoefs, John
Aulakh, Vikramjit S.
Treatment of Chronic HCV Infection in Special Populations
title Treatment of Chronic HCV Infection in Special Populations
title_full Treatment of Chronic HCV Infection in Special Populations
title_fullStr Treatment of Chronic HCV Infection in Special Populations
title_full_unstemmed Treatment of Chronic HCV Infection in Special Populations
title_short Treatment of Chronic HCV Infection in Special Populations
title_sort treatment of chronic hcv infection in special populations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1415846/
https://www.ncbi.nlm.nih.gov/pubmed/16614746
work_keys_str_mv AT hoefsjohn treatmentofchronichcvinfectioninspecialpopulations
AT aulakhvikramjits treatmentofchronichcvinfectioninspecialpopulations